TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03465761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate
Description: Bilateral side treatment of Essential Tremor
Study: NCT03796871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermapol
Description: Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
Study: NCT02295163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: 7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: 7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
Study: NCT04403269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgIV
Description: 2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
Study: NCT01555385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast juice
Description: single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast juice
Description: single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast juice
Description: single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
Study: NCT00722371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
Study: NCT01721681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FACTOR X
Study: NCT03327805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
Study: NCT03085550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting + platelet rich plasma
Description: Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
Study: NCT00255229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Glutamine 10 g four times daily starting two days before treatment for six days in total
Study: NCT03327805

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
Study: NCT00255229

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glutamine placebo
Study: NCT04349410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Azithromycin
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Doxycycline
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Clindamycin
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Clindamycin, Primaquine - low dose.
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Clindamycin, Primaquine - high dose.
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: FMTVDM Planar, SPECT, PET
Study: NCT00836056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg capsule
Description: 1 x 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cleocin HCl 300 mg capsules
Description: 1 x 300 mg
Study: NCT03872596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 25mg
Description: Administered during Part B, as a single, 25mg dose taken with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 25mg
Description: Administered during Part B, as a single, 25mg dose taken with water.
Study: NCT04349410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alpha2B
Description: FMTVDM Planar, SPECT, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: FMTVDM Planar, SPECT, PET
Study: NCT03872596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation A 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation A 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation A 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation B 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation B 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation B 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation 25mg
Description: Administered during Part B, as a single, 25mg dose taken with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation 25mg
Description: Administered during Part B, as a single, 25mg dose taken with water.
Study: NCT05247723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV Cannula for aspiration of testicular sperm
Description: After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-TESE
Description: Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
Study: NCT01933360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol sublingual, 1h
Description: Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual,1h
Description: Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol sublingual, 3h
Description: Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol vaginal, 1h
Description: Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol vaginal, 3h
Description: Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual, 3h
Description: Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vaginal, 1h
Description: Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vaginal, 3h
Description: Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
Study: NCT03157193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydroxypropyl Guar
Description: Hydroxypropyl Guar gel application as sham comparator
Study: NCT03222557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Refer to arm description

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Refer to arm description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Refer to arm description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Refer to arm description
Study: NCT00784472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: intravenous according to patients weight, pn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: intravenous administration according to patients weight, pn.
Study: NCT06023433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastomeric powerchain
Description: Canine distalization by engaging the elastomeric power chains onto the canine brackets.
Study: NCT04645914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of nicotine product (smoking/vaping)
Description: The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
Study: NCT01845376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia group
Description: Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia group
Description: Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia group
Description: Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
Study: NCT03836560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: nicotine patch given for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: nicotine patch given for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: nicotine gum given as requested
Study: NCT03753230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Cerebral measurements from electroencephalography devices while music is presented to the participant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Cerebral measurements from electroencephalography devices while music is presented to the participant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography
Description: Cerebral measurements from electroencephalography devices while music is presented to the participant
Study: NCT03466866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT
Description: Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EUC (Enhanced Usual Care)
Description: In-home diabetes education with no goal setting or telehealth visits
Study: NCT00500591

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
Study: NCT02259283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Knife
Description: POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
Study: NCT02508662

Intervention type: OTHER
Intervention: Review of Screening Tests and Molecular Test Results
Description: Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
Study: NCT03090568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
Study: NCT04499963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theracurmin HP
Description: The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
Study: NCT04349410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Serum
Description: FMTVDM Planar, SPECT, PET
Study: NCT01604811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permixon® 160 mg
Description: Oral administration - 160 mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosine Arrow LP
Description: Oral administration - 0.4 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.
Study: NCT03116867

Intervention type: OTHER
Intervention: sonosalpingography
Description: transvaginal ultrasound with saline infusion
Study: NCT02626611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
Study: NCT01604811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Tamsulosine Arrow LP
Description: Oral administration - daily.
Study: NCT01880060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INCENT weight loss program
Description: Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; \>20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
Study: NCT02626611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food Flour Buildup
Description: Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food Flour Buildup
Description: Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Food Flour Buildup
Description: Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
Study: NCT02927626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng therapy
Description: Yang Yin Fu Zheng is a Chinese herbal compound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine medical care
Description: Routine medical care
Study: NCT01334047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-006 vaccine
Description: Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
Study: NCT03334097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal education
Description: Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~1. St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~2. nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~3. rd: Puerperium.~4. rd :Breastfeeding~5. rd : Newborn care~6. rd :Positive parenting.
Study: NCT00111098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
Study: NCT01880060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Livin My Weigh
Description: Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
Study: NCT02352259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator Vitae®
Description: Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Description: Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
Study: NCT02259322

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Biweekly individual guided self-help sessions for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Biweekly individual guided self-help sessions for 3 months